Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP HARM: Watchman vs Anticoagulation in CKD
NCT02885545Phase 4Withdrawn
- Sponsor
- Population Health Research Institute
- Start
- Sep 2016
- Primary completion
- Mar 2018
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial (2 arms), sponsored by Population Health Research Institute. Primary endpoint: Time from randomization to the first occurrence of major bleeding at 5 years. Planned start Sep 2016; status: withdrawn.
Beyond the preview
Go deeper on NCT02885545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02885545.